Active, not recruitingEarly Phase 1NCT05560399

A Study of Iberdomide (CC-220) in Combination With Elotuzumab and Dexamethasone for Relapsed/Refractory Multiple Myeloma

Studying Plasma cell tumor

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Icahn School of Medicine at Mount Sinai
Principal Investigator
Samir Parekh, MBBS
Icahn school of medicine
Intervention
Iberdomide(drug)
Enrollment
7 enrolled
Eligibility
18 years · All sexes
Timeline
20232026

Study locations (1)

Collaborators

Multiple Myeloma Research Consortium · Bristol-Myers Squibb

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05560399 on ClinicalTrials.gov

Other trials for Plasma cell tumor

Additional recruiting or active studies for the same condition.

See all trials for Plasma cell tumor

← Back to all trials